308 related articles for article (PubMed ID: 33899554)
1. Protective Effects of Extracellular Matrix-Derived Hydrogels in Idiopathic Pulmonary Fibrosis.
Evangelista-Leite D; Carreira ACO; Gilpin SE; Miglino MA
Tissue Eng Part B Rev; 2022 Jun; 28(3):517-530. PubMed ID: 33899554
[TBL] [Abstract][Full Text] [Related]
2. The molecular mechanisms of extracellular matrix-derived hydrogel therapy in idiopathic pulmonary fibrosis models.
Evangelista-Leite D; Carreira ACO; Nishiyama MY; Gilpin SE; Miglino MA
Biomaterials; 2023 Nov; 302():122338. PubMed ID: 37820517
[TBL] [Abstract][Full Text] [Related]
3. Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis.
Tjin G; White ES; Faiz A; Sicard D; Tschumperlin DJ; Mahar A; Kable EPW; Burgess JK
Dis Model Mech; 2017 Nov; 10(11):1301-1312. PubMed ID: 29125826
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
5. Human lung extracellular matrix hydrogels resemble the stiffness and viscoelasticity of native lung tissue.
de Hilster RHJ; Sharma PK; Jonker MR; White ES; Gercama EA; Roobeek M; Timens W; Harmsen MC; Hylkema MN; Burgess JK
Am J Physiol Lung Cell Mol Physiol; 2020 Apr; 318(4):L698-L704. PubMed ID: 32048864
[TBL] [Abstract][Full Text] [Related]
6. Dicer1 Deficiency in the Idiopathic Pulmonary Fibrosis Fibroblastic Focus Promotes Fibrosis by Suppressing MicroRNA Biogenesis.
Herrera J; Beisang DJ; Peterson M; Forster C; Gilbertsen A; Benyumov A; Smith K; Korenczuk CE; Barocas VH; Guenther K; Hite R; Zhang L; Henke CA; Bitterman PB
Am J Respir Crit Care Med; 2018 Aug; 198(4):486-496. PubMed ID: 29579397
[TBL] [Abstract][Full Text] [Related]
7. Three dimensional fibrotic extracellular matrix directs microenvironment fiber remodeling by fibroblasts.
Nizamoglu M; Alleblas F; Koster T; Borghuis T; Vonk JM; Thomas MJ; White ES; Watson CK; Timens W; El Kasmi KC; Melgert BN; Heijink IH; Burgess JK
Acta Biomater; 2024 Mar; 177():118-131. PubMed ID: 38350556
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
9. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
10. Human pericytes adopt myofibroblast properties in the microenvironment of the IPF lung.
Sava P; Ramanathan A; Dobronyi A; Peng X; Sun H; Ledesma-Mendoza A; Herzog EL; Gonzalez AL
JCI Insight; 2017 Dec; 2(24):. PubMed ID: 29263297
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis.
Kliment CR; Oury TD
Free Radic Biol Med; 2010 Sep; 49(5):707-17. PubMed ID: 20452419
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis.
Zhu X; Ji J; Han X
J Mol Histol; 2024 Feb; 55(1):1-13. PubMed ID: 37878112
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets.
Ballester B; Milara J; Cortijo J
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30704051
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic pulmonary fibrosis: Current and future treatment.
Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; DeLeon J; Reiss AB
Clin Respir J; 2022 Feb; 16(2):84-96. PubMed ID: 35001525
[TBL] [Abstract][Full Text] [Related]
16. Anti-fibrotic strategies and pulmonary fibrosis.
Gunatilaka A; Zhang S; Tan WSD; G Stewart A
Adv Pharmacol; 2023; 98():179-224. PubMed ID: 37524487
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
18. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.
Huang Q; Chen Y; Shen S; Wang Y; Liu L; Wu S; Xu W; Zhao W; Lin M; Wu J
Aging (Albany NY); 2020 Apr; 12(7):5812-5831. PubMed ID: 32244228
[TBL] [Abstract][Full Text] [Related]
19. Chondroitin sulfate in tissue remodeling: Therapeutic implications for pulmonary fibrosis.
Kai Y; Yoneyama H; Yoshikawa M; Kimura H; Muro S
Respir Investig; 2021 Sep; 59(5):576-588. PubMed ID: 34176780
[TBL] [Abstract][Full Text] [Related]
20. Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis.
Mei Q; Liu Z; Zuo H; Yang Z; Qu J
Front Pharmacol; 2021; 12():797292. PubMed ID: 35126134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
